ChristopherJSweeneyMD

Associate Professor, Medicine-Brigham & Women's Hospital, Harvard Medical School

Dr. Sweeney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
44 Binney St
# D1230
Boston, MA 02115
Phone+1 617-632-4524

Fax+1 617-632-2165

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1997 - 2001
Gundersen Lutheran Medical FoundationResidency, Internal Medicine, 1994 - 1997
The University of Adelaide Faculty of Health SciencesClass of 1993

PubMed

Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, Andrew J Martin, Wendy Parulekar
Future Oncology. 2025-01-17
Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.
Katherine L Morel, Beatriz Germán, Anis A Hamid, Jagpreet S Nanda, Simon Linder
The Journal of Clinical Investigation. 2024-11-19
Reply to J.A. Garcia et al.
Susan Halabi, Siyuan Guo, Akash Roy, Larysa E Rydzewska, Peter Godolphin
Journal of Clinical Oncology. 2024-08-20

Journal Articles

A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer
Christopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration
Richard S Foster, Lawrence H Einhorn, Christopher J Sweeney, Guru Sonpavde, Costantine Albany, Chandra K Flack, The Journal of Urology

Lectures

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer...
2019 ASCO Annual Meeting - 6/1/2019
Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progres...
2019 ASCO Annual Meeting - 6/1/2019

Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?July 2018

7 Sneaky Signs of Testicular CancerApril 29th, 2022
UT Student Diagnosed with Testicular Cancer at 17 Years Old Shares Story to Educate OthersApril 28th, 2021
How Has the Covid-19 Pandemic Impacted Cancer Research?January 13th, 2021
Join now to see all

Evaluating A Parthenolide Analogue As A New Bladder And Kidney Cancer TherapyNational Cancer Institute2011–2012
Phase I, Pharmacokinetic, Pharmacodynamic Trial Of PTK787 And Paclitaxel In CNational Center For Research Resources2006–2008
A Pharmacokinetic And Pharmacogenetic Study Of ChemotherapeuticNational Center For Research Resources2006–2008
Phase I Dose Escalation Study To Determine The Safety,Pharmacokinetics AndNational Center For Research Resources2006
A Phase I Study Of OSI-461 In Combination With Mitoxantrone (Novantrone ) InNational Center For Research Resources2006
A Phase 1 Safety And Pharmacokinetic Study Of Su011248 And Capecitabine In PANational Center For Research Resources2006
OSI-774 In Combo W/Weekly Docetaxel In PTS W/Taxane Naive MalignanciesNational Center For Research Resources2004–2006